Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Roth MKM Maintains Buy on Mind Medicine, Raises Price Target to $36

Author: Benzinga Newsdesk | March 07, 2024 12:35pm
Roth MKM analyst Jonathan Aschoff maintains Mind Medicine (NASDAQ:MNMD) with a Buy and raises the price target from $25 to $36.

Posted In: MNMD

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist